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MTH is an effective neuroprotective therapy in patients after cardiac arrest. Therapeutic
hypothermia is recommended as a standard resuscitation care in such patients with VF/VT
as initial rhythm. MTH is easy to perform and without severe side-effects or complications
associated with mortality. The goal of the first part of review concentrating on MTH is to
describe the mechanism of action, tools for cooling, and adverse events related to this
therapeutic technique after the cardiac arrest.
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Table 1 – Randomized controlled trials of mild therapeutic hypothermia after cardiac arrest.
Study Number
of
patients
Cooling
mechanism
Initial
rhythm
Target
temperature
Survival
(hypothermia vs.
control)
Favourable neurological outcome
(hypothermia vs. control)
HACA study
group [2]
136 vs.
137
External VF/VT 32–34 1C for
24 h
59% vs. 45% at 6
months
CPC 1-2
p¼0.02 55% vs. 39% at 6 months
p¼0.009
Bernard [3] 43 vs. 34 External VF 33 1C for
12 h
49% vs. 32% at
discharge
CPC1-2
ns. 49% vs 26% at discharge
p¼0.046
Kim [36] 63 vs. 62 Cold
intravenous
infusion
All
rhythm
33 1C for
24 h
33% vs. 29% at
discharge
–
ns.
Castren
PRINCE trial
[37]
93 vs. 101 Intra-nasal
cooling
system
All
rhythm
Unknown 44% vs .31% at
discharge
34% vs 21% at discharge
ns. ns.
56% vs. 30% 43% vs. 18%
For CRP within
10 min
For CPR within 10 min
p¼0.04 p¼0.03
VF—ventricular fibrillation, VT—ventricular tachycardia, CPC—cerebral performance categories, CPR—cardiopulmonary resuscitation.
Fig. 1 – Mechanism by which cerebral ischemia causes
neuronal damage. (ATP—adenosine triphosphate, TNF-a
tumor necrosis factor-a, IL-1—interleukin 1).
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The incidence of cardiac arrest in Europe is estimated
between 0.4–1 per 100 inhabitants per year, which counts
between 350 000–700 000 people affected [1]. After the pub-
lication of two landmark studies [2,3] in 2002, mild therapeu-
tic hypothermia (MTH) began to be used increasingly be used
in post-resuscitation care. In the same year, the Advanced
Life Support Task Force of the International Liaison Commit-
tee on Resuscitation stated in their recommendations that
unconscious adult patients with spontaneous circulation
after an out-of hospital cardiac arrest (OHCA) should be
cooled to 32–34 1C for 12 h to 24 h when the initial rhythm
was ventricular fibrillation (VF) [4]. In 2005, The American
Heart Association incorporated MTH into its advanced car-
diac life support guidelines as the late link of the chain of
survival [5]. The International Liaison Committee on Resus-
citation strongly suggests MTH for comatose survivors after
cardiac arrest in their last Recommendation published in
2010 [6]. Recent consensus document from five international
critical care societies have made the same recommendation
[7]. MTH is also recommended by Czech profession societies
[8].
The goal of the first part of review concentrating on MTH is
to describe the mechanism of action, tools for cooling, and
adverse events related to this therapeutic technique after the
cardiac arrest Table 1.2. History of therapeutic hypothermia
The therapeutic use of hypothermia has a long history. In
antiquity, Hyppocrates already saved wounded soldiers in
snow and ice. In the Napoleonic time the surgeon Dominique
Jean Larrey noted that officers who were kept closer to the fire
survived less often than soldiers who slept away from fire.The first study dealing with therapeutic hypothermia in
patients with severe head injury was published in 1945 [9].
The use of therapeutic hypothermia after cardiac arrest in
humans was described in 1950s, but with uncertain benefits
[10,11]. The use of MTH as a tool to reduce cerebral oxygen
demand and to improve neurological outcomes after cardiac
arrest was supported by studies in dogs [12–14]. After 1998,
the interest in MTH increased and first clinical studies in
humans after cardiac arrest were realized and published
[15,16].3. Mechanism of action
MTH is nowadays one of the most important methods of
neuroprotection. Understanding the mechanisms of action,
through which MTH provides neuroprotection, will allow a
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 3 7 – e 2 4 2 e239better understanding about the indications for this therapy
(Fig. 1).
After the cardiac arrest, level of oxygen decreases and an
ischemic cascade takes place. The permanent damage of
neuronal cells occurs after 5 min to 10 min of complete blood
flow cessation [17].
During the ischemia-reperfusion time the reduction in
high-energy molecules, such as adenosine triphosphate
(ATP), takes place. The consequence of this decrease leads
to a change in metabolism from aerobic to anaerobic. Anae-
robic glycolysis increases intracellular phosphate, lactate and
hydrogen ions levels, resulting in intra- and extra-cellular
acidosis. The acidosis increases the inflow of calcium to the
cell. The acidosis and high calcium levels also stimulate the
cell apoptosis and cause cell death [18].
The concentration of intracellular calcium increases [19]
Calcium enters the cell through voltage-sensitive calcium
channels and agonist-operated calcium channels [20]. There
is a dysfunction of sodium/potassium ATP-dependent pump
and ATP-dependent channels, such as calcium, sodium, and
potassium channels. This limits the calcium output from the
cell and the levels of intracellular calcium further increase.
The calcium inflow leads to cell membranes depolarization
and extracellular release of excitatory neurotransmitters
such as glutamate, activating kainite/quisqualate and
N-methyl-D-aspartate receptors persistently [21]. The activa-
tion of these receptors leads to an influx of sodium and
chloride into the cell, causing intracellular hyperosmolarity.
The high osmolarity is followed by an influx of water into the
cell, resulting in intracellular edema and neuronal death [22].
Ischemia with subsequent reperfusion generates large
amounts of free radicals such as hydrogen peroxide, super
oxide and peroxynitrite. These molecules cause cell mem-
branes peroxydation and play an important role in brain
damage after ischemia [23]. There is also an increased
production of pro-inflammatory mediators such as tumor
necrosis factor— a and interleukin 1 [24].
MTH reduces cerebral metabolic rate for oxygen by 6%–10%
for every 1 1C temperature reduction [25]. Hypothermia is
likely to lower lactate levels and other wastes from anaerobic
metabolism decreasing cellular acidosis [26]. Hypothermia
significantly reduces extracellular levels of excitatory neuro-
transmitters, including dopamine and glutamate [27]. The
release of these neurotransmitters is temperature dependent
[28]. The production of free radicals is associated with
oxidative damage that is minimized at lower temperatures
[29]. Hypothermia also delays the induction of pro-inflam-
matory cytokines in human peripheral blood [30].4. Initiation, duration of MTH, and cooling
techniques
4.1. Initiation
MTHmay be divided into three parts: induction, maintenance
and re-warming. The impact of timing of initiation of MTH in
patients after cardiac arrest remains unclear. Experimental
data suggest that MTH should be initiated as soon as possible
[31–33]. However, the initiation of MTH in pre-hospital settingdid not have any impact on neurological outcome in patients
[34]. Two prospective clinical trials in which hypothermia was
achieved within 2 h [3] or at a median of 8 h (interquartile
range 4–16 h) [2] after return of spontaneous circulation
(ROSC) demonstrated better outcomes in the hypothermia-
treated than the normothermia-treated subjects.
Pre-hospital versus in-hospital cooling has been studied in
randomized control trial performed by Bernard at al. [35]
Patients with VF as initial rhythm after the ROSC (n¼234)
have been included. The studied arm received two liters of
ice-cold Ringer’s solution from paramedics whilst the other
arm received cooling after arrival to the hospital using the
same method. No significant difference was observed in
favorable neurological outcome at discharge between the
two study arms (47.5% in the pre-hospital cooled group and
52.6% in the hospital-cooled group, respectively). In the study
from Kim et al. [36], 63 patients were randomized to receive
an infusion of 0.5 l to 2.0 l of 4 1C normal saline before
hospital arrival, 62 patients were left without intravenous
cooling during the pre-hospital care. In-field cooling was not
associated with increased complications, such as pulmonary
edema. There was no significant difference in survival
between the two groups. This study was limited by short
transport times and missing temperature data.
Castre´n at al. studied the intra-arrest cooling. The OHCA
survivors were randomized to receive either trans-nasal
cooling (93 patients) or standard care (101 patients) during
cardiopulmonary resuscitation. After the ROSC, trans-nasal
cooling continued in the studied group, in the second group
MTH was initiated after hospital admission and continued for
24 h. Time to target temperature of 34 1C was shorter in the
treatment group for tympanic temperature (102 min in the
trans-nasally cooled group versus 282 min in control group,
respectively, p¼0.03) not for core temperature (155 versus
284 min, p¼0.13). Moreover, neurological outcomes (cerebral
performance categories (CPC) scale 1 to 2 at discharge: 34% in
the trans-nasally cooled group and 21% in the control group,
respectively) and overall survival rates (44% versus 31%) were
similar in both groups [37].4.2. Duration
The optimal duration of cooling must not be shorter than
12 h, and may last up to 24 h. Hypothermia was maintained
for 12 h [3] or 24 h [2] in studies of OHCA patients presenting
with VF. Moreover, most of the clinical trials maintained the
MTH for 24 h. Longer duration of MTH has not been studied
in adults, but hypothermia for up to 72 h has been used safely
in newborns [38].4.3. Re-warming
Re-warming can be achieved with the same external or
internal temperature control devices used for cooling. It
usually starts after 24 h of MTH. There is no consensus about
the rate of re-warming, but it should be no greater than
0.25–0.5 1C per hour [39]. After the re-warming, hyperthermia
should be actively avoided. MTH may lead to an increased
concentration of sedative drugs because their clearance is
Fig. 2 – Patient after cardiac arrest cooled by ice packs, wet
towel and fanning. The temperature is monitored using
bladder probe.
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after 48–72 h after re-warming.
4.4. Cooling techniques
Invasive and non-invasive cooling methods are available for
the use in OHCA patients. Intravenous infusion of ice-cold
(4 1C) fluids (up to 30 ml kg1 of saline 0.9% or Ringer’s lactate
solution) has been shown to adequately induce MTH and is
easy to use in the pre-hospital setting [41,42]. Could fluid
infusion alone is not sufficient to maintain MTH [43]. The
same effect in inducing and maintaining of MTH have ice
packs placed in the groins, armpits and around the head and
neck or use of wet towels and fanning. Ice packs are
inexpensive and easy to use but have no temperature feed-
back control and may cause subject over-cooling. Other
external surface cooling methods include cooling blankets
or fluid pads. It depends on external energy support and is
therefore less portable. On the other hand, they operate with
a continuous temperature feedback control. The usual cool-
ing rate is up to 1.2 1C per hour [44]. Cooling by peritoneal,
pleural or bladder lavage is possible but not generally used.
The endovascular cooling system consists of an endovascular
catheter containing circulating fluid. It can achieve the cool-
ing rate of 1.5–4.5 1C. For the insertion of the catheter a large
vein is needed with its possible thrombo-embolic or infec-
tious complications.
An alternative to whole body cooling is brain hypothermia.
Using cranial cap devise placed around the head and neck
can be easily achieved the tympanic temperature of 34 1C in
60 min. The Pre ROSC Intranasal Cooling Effectiveness
(PRINCE) trial demonstrated safety and efficacy of nasophar-
yngeal cooling. This device delivers perfluorocarbon aerosol
via a catheter into the nasopharynx and provides preferential
brain cooling [37].
Tomte et al. [45] compared intravascular and surface cool-
ing techniques in comatose cardiac arrest survivors in a non-
randomized study. One hundred sixty seven consecutive
patients were included in the study during the five-year
recruitment period. There was no significant difference in
survival with good neurologic function, either to hospital
discharge (38% in surface-cooled group and 45% in intravas-
cular-cooled group, respectively) or at 6-month follow-up
(39% versus 45%). Time from cardiac arrest to achieve MTH
was equal for both devices (surface-cooled group median
273 min., inter-quartile range 158–330 min. and intravascular-
cooled group 270 min., inter-quartile range 190–360 min.).
The patient’s core temperature is most commonly mon-
itored with a probe in the esophagus, bladder, rectum,
pulmonary artery or by tympanic temperature measure-
ments [46]. During the cooling, patients are sedated generally
by the use of opioids and benzodiazepines. To eliminate the
natural body response to decrease in core temperature –
shivering – neuromuscular blockers are used.
In our coronary care units, we use ice-cold Saline solution
(30 ml per kilogram during the first 30 min) during the
coronary angiography or after the admission. Subsequently,
we apply refrigerated cooling packs around the head, neck,
trunk and groins in the combination with wet towels and
fanning (Fig. 2). Before the induction of MTH patients aresedated using midazolam and fentanyl. To prevent shivering,
paralysis is induced by intravenous administration of pan-
curonium as a bolus that is repeated every 4 h. The tempera-
ture is controlled by bladder catheter continuously. MTH is
maintained for 24 h. Patients are re-warmed passively, with
the re-warming rate of 0.5 1C per hour. Sedation is discon-
tinued after the core body temperature of 36 1C is reached.
During the next 72 h, we maintain core body temperature
between normal ranges. Hyperthermia is actively treated by
administration of metamizolum.5. Adverse effects
The most often reported adverse effects of MTH include hypo-
kalemia, hypomagnesemia, hypocalcaemia, arrhythmias, hypo-
tension, seizure, hyperglycemia, coagulopathy and increased
incidence of pneumonia and sepsis. Hypokalemia induced by
MTH is caused by the influx of potassium into the cells and
increased diuresis. Regular checks of mineralogram are neces-
sary during MTH. On the other hand, aggressive supplementa-
tion of potassium during MTH may result in hyperkalemia
during re-warming [47]. MTH reduces insulin sensitivity and
insulin secretion. Both of these may lead to hyperglycemia [48].
Enzymes taking part in coagulations have lower activity with
hypothermia. Bleeding must be watched for and if occurs,
interruption of MTH is indicated. Some authors reported the
Fig. 3 – Hypothermia flow chart (modified by Delhaye et al.
[52]).
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sially, in the randomized trial published by Tiainen et al. [50] the
use of MTH of 33 1C for 24 h after cardiac arrest was not
associated with an increase in clinically significant arrhythmias
Fig. 3.
In the prospective, observational, registry-based study per-
formed in 22 hospitals in Europe and United States the
association between adverse events recorded during critical
care and mortality in out-of-hospital cardiac arrest patients
(n¼765) treated with therapeutic hypothermia was studied.
Only sustained hyperglycemia (odds ratio 2.3, 95% CI 1.6–3.6,
po0.001) and seizures treated with anticonvulsants (odds
ratio 4.8, 95% CI 2.9–8.1, po0.001) were associated with
increased mortality in a multivariate model. An increased
frequency of bleeding and sepsis occurred after invasive
procedures (coronary angiography, intravascular devices for
cooling, intra-aortic balloon pump), but bleeding and sepsis
were not independently associated with increased mortality
(odds ratio 1.0, 95% CI 0.46–2.2, p¼0.91, and odds ratio 0.30,
95% CI 0.12–0.79, p¼0.01, respectively) [51].6. Conclusion
MTH is an effective neuroprotective therapy in patients after
cardiac arrest. Therapeutic hypothermia is recommended as
a standard resuscitation care in patients after cardiac arrest.
MTH is easy to perform and without severe side-effects or
complications associated with mortality. MTH should be
initiated as soon as possible. Finally, at this time, we recom-
mend the use of MTH in all cardiac arrest survivors irrespec-
tive of initial rhythm who remain unconscious after ROCS to
increase the chance of brain recovery after the ischemic-
reperfusion injury. The optimal duration and target tempera-
ture will be hopefully known after the results of ongoing
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